BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema.
The company’s chief business officer, referred to in the transcript as BJ, said BioAge is a clinical-stage biotech founded on the idea that human aging biology can be used to identify drug targets for cardiometabolic disease. He described BGE-102 as a potential best-in-class NLRP3 inhibitor being developed for cardiovascular disease and ophthalmology.